Hasil Pencarian (1)
small molecule | CAS: 1903008-80-9
Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).[A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small…
Kategori:
Antineoplastic AgentsAntineoplastic and Immunomodulating AgentsBCRP/ABCG2 Inhibitors
+14
Target Protein:
Epidermal growth factor receptor
Waktu ParuhThe mean terminal h…
Vol. DistribusiThe mean apparent v…
KlirensThe mean apparent c…
Genetik
-